• Oct 26, 2026

  $104.88+1.14%

• Oct 23, 2026

  $103.70+1.16%

  Abbott rose 1.16% while comparable Pharmaceutical Preparations companies fell 1.45% on average, with 5 of 6 declining [1]. The move was therefore not shared by the cohort, and only ABBV among the listed peers also rose (+0.16%) [1].

  • 1Peer group

• Oct 22, 2026

  $102.51+1.99%

  Abbott rose 1.99% while comparable pharmaceutical companies rose 1.18% on average, with 5 of 6 advancing [1]. The move came alongside a gain across the cohort, though Abbott's was larger.

  • 1Peer group

• Oct 21, 2026

  $100.51-1.89%

  Abbott reported third-quarter 2026 results and reaffirmed full-year EPS guidance [1]. Seeking Alpha reported the stock slipped after a cut to its 2026 growth outlook, alongside plans to separate its nutrition business as a public company by 2027 [2][3]. Comparable pharmaceutical companies were nearly flat, down 0.08% on average [4], so the decline was not shared by the cohort. Volume was 2.5x the trailing 20-session average, and the session ranged from 97.67 to 106.35 [5].

  • 1Pr Newswire
  • 2Seeking Alpha
  • 3Seeking Alpha
  • 4Peer group
  • 5Market data

• Oct 20, 2026

  $102.45-1.55%

  Abbott fell 1.55% while comparable pharmaceutical companies rose 3.07% on average, with all six rising [1]. The decline was therefore not shared by the group. Volume was 1.5x the trailing average [2].

  • 1Peer group
  • 2Market data

• Oct 19, 2026

  $104.06-0.79%

  Abbott shares fell 0.79% alongside comparable pharmaceutical companies, which moved -0.87% on average, with 5 of 6 lower [1]. The decline was broadly in line with the cohort.

  • 1Peer group

• Oct 16, 2026

  $104.89+0.20%

Closing prices for ABT. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.